Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)

Most if not all vaccine candidates developed to combat COVID-19 due to SARS-CoV-2 infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious respiratory fluids, vaccine-induced mucosal immunity could provide an important contribution to control this pandemic. ChAd-SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunagar, Raju, Prasad, Sai D., Ella, Raches, Vadrevu, Krishna Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773076/
https://www.ncbi.nlm.nih.gov/pubmed/36569867
http://dx.doi.org/10.3389/fimmu.2022.1063679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773076/
https://www.ncbi.nlm.nih.gov/pubmed/36569867
http://dx.doi.org/10.3389/fimmu.2022.1063679

Ejemplares similares